Pfizer
Pfizer to buy Hospira for $17 billion
February 5, 2015Sales and Marketing Hospira, Humira, Pfizer, acquisition, biosimilars, merger
Pfizer has struck a deal with Hospira to acquire the company in a deal worth around $17 billion. Industry analysts …
Pfizer gets early approval for breast cancer drug
February 4, 2015Sales and Marketing FDA, Pfizer, Xalkori (crizotinib), axitinib, bosulif, bosutinib, femara, ibrance, inlyta, letrozole, palbociclib
The FDA has shown Pfizer’s breast cancer drug Ibrance an early green light to treat patients who are at the …
Pfizer posts fourth-quarter revenue decline
January 28, 2015Sales and Marketing Eliquis, Lipitor, Lyrica (pregablin), Pfizer, Read, Xeljanz, apixaban, financials, pneumococcal vaccine Prevnar, q4, tofacitinib citrate
Pfizer posted a 3% decline in revenue in the last quarter of 2014, the company’s latest financial results show. The …
Pharma firms pledge vaccine support for developing countries
January 27, 2015Manufacturing and Production, Research and Development, Sales and Marketing GAVI, GSK, Janssen, Médecins Sans Frontières, Pfizer, Vaccine
Several pharma firms have announced commitments to help Gavi, the global vaccine alliance, to increase immunisation of children in developing …
MSF hits out at ‘astronomical’ vaccine prices
January 20, 2015Research and Development, Sales and Marketing Doctors Without Borders, GSK, Médicines San Frontières, Pfizer, Vaccine, diphtheria, measles, pertussis, poliomyelitis, tetanus, tuberculosis
Pharma companies have been named and shamed in a report calling on manufacturers to lower the cost of childhood vaccines …
Daiichi-Sankyo blood drug gets FDA nod
January 12, 2015Sales and Marketing BMS, Daiichi Sankyo, Daiichi-Sankyo, FDA, Pfizer, Pradaxa, atrial fibrillation, blood, savaysa
The US Food and Drug Administration has shown Daiichi-Sankyo’s anti-clotting drug Savaysa the green light to reduce the risk of …
Genentech makes $10m gene testing outlay
January 8, 2015Medical Communications, Research and Development, Sales and Marketing 23andME, DNA, Genentech, MHRA, Pfizer, Roche
Genentech has thrown its weight behind the contentious DNA testing company 23andMe, by agreeing a deal to buy the genomic …
Pfizer buys vaccine developer Redvax
January 6, 2015Research and Development, Sales and Marketing Pfizer, Vaccine, cmv, herpes, redbiotec, redvax, virus
Adding to its latest string of deals Pfizer has acquired vaccine developer Redvax – the pre-clinical arm of Swiss company …
New Lyrica formulation effective in trials
December 19, 2014Sales and Marketing HIV, Lyrica, Pfizer, pain, pregabalin, shingles
Pfizer has reported positive Phase III results for a new formulation of its painkiller Lyrica. In the study, a controlled-release …
Big pharma spent $112 billion on R&D in 2013
December 17, 2014Research and Development, Sales and Marketing Merck, Pfizer, R&D, Roche, data, global data, research
The top 30 pharma companies spent a combined total of $112 billion on research and development last year. Calculated to …
NICE backs Pfizer’s drug for advanced kidney cancer
December 16, 2014Sales and Marketing NICE, Pfizer, Sutent, Votrient, Zytiga, axitinib, inlyta, xofigo
UK healthcare guidance body NICE has issued final draft guidance recommending Pfizer’s Inlyta for advanced kidney cancer. The draft recommendation …
Pfizer buys OPKO growth hormone drug
December 16, 2014Research and Development, Sales and Marketing Pfizer, ghd, growth, hGH-CTP, hormone, merger, opko
Pfizer will co-develop and commercialise OPKO’s growth hormone deficiency (GHD) drug hGH-CTP in a new agreement between the firms. The …
Pfizer buys into gene therapy
December 9, 2014Research and Development, Sales and Marketing London, Pfizer, gene therapy, haemophilia, spark, therapeutics
Pfizer has announced that it is establishing a gene therapy platform as it looks to expand its rare diseases operations. …
AZ predicts strong growth ahead of Pfizer deadline
November 19, 2014Sales and Marketing AZD9291, AstraZeneca, Pfizer, Soriot, definiens
AstraZeneca has announced that it expects to deliver revenues of over $45 billion by 2023 as it makes its final …
Pfizer signs $3 billion cancer deal
November 18, 2014Research and Development, Sales and Marketing Cancer, Merck KGaA, PD-L1, Pfizer, anti-PD-L1, opdivo
Pfizer has signed a multi-billion dollar deal to develop one of Merck KGaA’s investigational drugs, MSB0010718C, an anti-PD-L1 antibody. The …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
